Abstract
Tamsulosin HCl is an αq-1 adrenergic receptor antagonist that is primarily used to treat benign prostatic hyperplasia (BPH), a disease defined by an enlarged prostate. The aim of this project is to develop, analyze, and compare the developed formulations to the innovator product (Flomax). The formulations were prepared by integrating Eudragit L100-55 as enteric polymers in various formulations, Drug coat L30D as a sustained release coating polymer, and PEG 6000 as pore forming in distinct quantities. The formulation F8 exhibited %CDR of 98.8%, comparable to the Flomax (innovator product) and the similarity factor (f2) was calculated and found to be 94.3% marking this formulation equivalent to the innovate product. The improved formulation was tested for stability for the 1st month at 40 ± 2°C and 75 ± 5% R_H, as per ICH guidelines. The regression results of the improved formulation led to an inference that F8 indicates first-order kinetics with an estimated regression value of 0.926, and it was concluded that the drug had been released through diffusion mechanism.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callSimilar Papers
More From: Saudi Journal of Medical and Pharmaceutical Sciences
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
